Cartesian Therapeutics (NASDAQ: RNAC)
NASDAQ: RNACWatertown, US · Delaware corporation · 7 known investors
Find your way into Cartesian Therapeutics (NASDAQ: RNAC)
1,679 people in our graph share verified history with the Cartesian Therapeutics (NASDAQ: RNAC) team — schools, employers, funds. One of them is your warm intro.
Wesley Chanunlockedknows Lloyd Johnston · together at Massachusetts Institute of Technology (overlapped)
×4knows the team · via Massachusetts Institute of Technology
knows the team · via Harvard University
×4knows the team · via Middlebury College
knows the team · via Lehigh University
knows the team · via Akzo Nobel
Cartesian Therapeutics is a clinical-stage biotechnology company developing mRNA-based cell therapies aimed at treating autoimmune diseases. It focuses on immunology and applies an mRNA platform to broaden the use of cell therapy for patients.
Founders & leadership
MK
Metin KurtogluCo-founder
OF
Omid FarokhzadCo-founder
CJ
Chris JewellinChief Scientific Officer and Senior Vice President2023–2026Christopher Jewell is Chief Scientific Officer at Cartesian Therapeutics and an Institute Professor of Translational Engineering at the University of Maryland. He has over 20 years of experience in biotechnology spanning R&D, founding multiple companies, management consulting at Boston Consulting Group, and academic research in immunology and cell therapy, with a PhD in Chemical Engineering from the University of Wisconsin and a dual degree in Chemical Engineering and Molecular Biology from Lehigh University.
CB
Carsten BrunninPresident and CEOCarsten Brunn has over 25 years of global leadership experience in biopharma, including prior roles leading two NASDAQ-listed biotech companies where he raised over $500 million in capital. He brings expertise in mRNA cell therapy, immune tolerance, and rare disease therapeutics.
EE
Emily EnglishinChief Operations Officer
BD
Blaine DavisinChief Financial OfficerBlaine Davis is an Executive Officer at Cartesian Therapeutics, a clinical-stage biotechnology company developing mRNA-based cell therapies for autoimmune diseases. He brings experience in financial leadership and general management within the life sciences sector.
SS
Stephen SmolinksiExecutive
LJ
Lloyd JohnstoninExecutiveLloyd Johnston has over 25 years of biotechnology industry experience, focusing on drug development, manufacturing, and regulatory affairs across multiple modalities, including small molecules, biologics, and gene therapies. He has contributed to the development of multiple approved products and supported numerous clinical programs from IND through commercial approval.
BD
Bradford D. DahmsExecutive
TK
Takashi Kei KishimotoExecutive
WC
Werner CautreelsExecutive
DS
David SiewersExecutive
Investors · 7
Reported raises · per SEC filings
Form D private placements$405.1M disclosed across 12 of 15 rounds · 1900–2024
▶$130MraisedJul 2024 · 22 investors · BiotechnologyRule 506(b)
▶$130MraisedJul 2024 · 22 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Chris JewellExecutive Officer
- Michael SingerDirector
- Kemal MalikDirector
- Carsten BrunnExecutive Officer, Director
- Metin KurtogluExecutive Officer
- Timothy C. BarabeDirector
- Timothy A. SpringerDirector
- Nishan de SilvaDirector
- Patrick ZennerDirector
- Emily EnglishExecutive Officer
- Carrie S. CoxDirector
- Blaine DavisExecutive Officer
- Murat KalayogluDirector
- Milos MiljkovicExecutive Officer
- Offering amount
- $130M
- Amount sold
- $130M
- Sales commissions
- $5M
- First sale
- Jul 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$60.3MraisedDec 2023 · 2 investors · BiotechnologyRule 506(b)
▶$60.3MraisedDec 2023 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Timothy SpringerDirector
- Metin KurtogluExecutive Officer
- Aymeric SallinDirector
- Milos MiljkovicExecutive Officer
- Blaine DavisExecutive Officer
- Timothy BarabeDirector
- Murat KalayogluDirector
- Patrick ZennerDirector
- Michael SingerDirector
- Nishan De SilvaDirector
- Carsten BrunnExecutive Officer, Director
- Carrie S. CoxDirector
- Chris JewellExecutive Officer
- Offering amount
- $60.3M
- Amount sold
- $60.3M
- First sale
- Nov 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$25MraisedAug 2020 · 1 investors · BiotechnologyRule 506(b)
▶$25MraisedAug 2020 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Stephen SmolinksiExecutive Officer
- Lloyd JohnstonExecutive Officer
- Carrie CoxDirector
- Timothy SpringerDirector
- Scott MyersDirector
- Timothy BarabeDirector
- Bradford D. DahmsExecutive Officer
- Carsten BrunnExecutive Officer, Director
- Takashi Kei KishimotoExecutive Officer
- Goran AndoDirector
- Patrick ZennerDirector
- Aymeric SallinDirector
- Elona KoganExecutive Officer
- Offering amount
- $25M
- Amount sold
- $25M
- First sale
- Jul 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$70MraisedJan 2020 · 26 investors · BiotechnologyRule 506(b)
▶$70MraisedJan 2020 · 26 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Elona KoganExecutive Officer
- Stephen SmolinskiExecutive Officer
- Amir NashatDirector
- Scott Dunseth MyersDirector
- Aymeric SallinDirector
- Timothy SpringerDirector
- Patrick ZennerDirector
- Alison SchecterExecutive Officer
- Timothy BarabeDirector
- Carsten BrunnExecutive Officer, Director
- Bradford DahmsExecutive Officer
- Lloyd JohnstonExecutive Officer
- Takashi Kei KishimotoExecutive Officer
- Carrie CoxDirector
- Offering amount
- $70M
- Amount sold
- $70M
- Sales commissions
- $4.2M
- Placement agents
- Cantor Fitzgerald LP, Janney Montgomery Scott LLC, Canaccord Genuity LLC, Needham & Company
- First sale
- Dec 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.8MraisedSep 2019 · 10 investors · BiotechnologyRule 506(b)
▶$5.8MraisedSep 2019 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Patrick ZennerDirector
- Timothy SpringerDirector
- Aymeric SallinDirector
- Amir NashatDirector
- Timothy BarabeDirector
- Omid FarokhzadDirector
- Alison SchecterExecutive Officer
- Stephen SmolinskiExecutive Officer
- Elona KoganExecutive Officer
- Scott D. MyersDirector
- Carsten BrunnExecutive Officer, Director
- Lloyd JohnstonExecutive Officer
- Takashi Kei KishimotoExecutive Officer
- Offering amount
- $5.8M
- Amount sold
- $5.8M
- First sale
- Aug 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$50MraisedJul 2017 · 11 investors · BiotechnologyRule 506(b)
▶$50MraisedJul 2017 · 11 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David AbrahamExecutive Officer
- Werner CautreelsExecutive Officer, Director
- Earl SandsExecutive Officer
- Omid FarokhzadDirector
- Patrick ZennerDirector
- Aymeric SallinDirector
- Timothy SpringerDirector
- Timothy C. BarabeDirector
- Peter KellerExecutive Officer
- Takashi Kei KishimotoExecutive Officer
- David SiewersExecutive Officer
- Lloyd JohnstonExecutive Officer
- Amir NashatDirector
- Peter Barton HuttDirector
- Offering amount
- $50M
- Amount sold
- $50M
- Sales commissions
- $2.6M
- Placement agents
- Stifel, Nicolaus & Company Incorporated
- First sale
- Jun 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5MraisedDec 2016 · 1 investors · BiotechnologyRule 506(b)
▶$5MraisedDec 2016 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Peter Barton HuttDirector
- Takashi Kei KishimotoExecutive Officer
- Amir NashatDirector
- Aymeric SallinDirector
- Carl GordonDirector
- Omid FarokhzadDirector
- Lloyd JohnstonExecutive Officer
- Edwin M. Kania, Jr.Director
- Timothy C. BarabeDirector
- David SiewersExecutive Officer
- Peter KellerExecutive Officer
- Earl SandsExecutive Officer
- Timothy SpringerDirector
- Werner CautreelsExecutive Officer, Director
- David AbrahamExecutive Officer
- Offering amount
- $5M
- Amount sold
- $5M
- First sale
- Dec 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$37.4MraisedSep 2015 · 19 investors · BiotechnologyRule 506(b)
▶$37.4MraisedSep 2015 · 19 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Takashi Kei KishimotoExecutive Officer
- Aymeric SallinDirector
- Lloyd JohnstonExecutive Officer
- Amir NashatDirector
- Omid FarokhzadDirector
- Robert LangerDirector
- Leysan ShaydullinaDirector
- David AbrahamExecutive Officer
- Peter KellerExecutive Officer
- David SiewersExecutive Officer
- Earl SandsExecutive Officer
- Werner CautreelsExecutive Officer, Director
- Edwin M. Kania, Jr.Director
- Carl GordonDirector
- George SiberDirector
- Peter Barton HuttDirector
- Offering amount
- $40.6M
- Amount sold
- $37.4M
- First sale
- Aug 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlapKite Pharma62 shared keywordsKite develops CAR T-cell therapies that engineer a patient's own immune cells to target and destroy cancer cells. The company focuses on cell therapy treatments for cancers such as diffuse large B-cell lymphoma.
Dialectic Therapeutics41 shared keywordsDialectic Therapeutics is a clinical-stage biotechnology company developing anti-cancer drugs using its Antiapoptotic Protein Targeted Degradation (APTaD) platform, which induces cancer cells to degrade proteins such as BCL-XL. Its lead candidate, DT2216, is in Phase 1/2 trials for fibrolamellar carcinoma and platinum-resistant ovarian cancer.
Solu33 shared keywordsSolu Therapeutics is a clinical-stage biotech developing a class of antibody therapeutics that link bifunctional small molecules to proprietary effector antibodies (its CyTAC and TicTAC platforms) to reach cell surface targets like GPCRs and ion channels. Its pipeline targets oncology, immunology and inflammation, and pain, with a lead program in Phase 1 trials for chronic myelomonocytic leukemia.
Companies competing with Cartesian Therapeutics (NASDAQ: RNAC) for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 4 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2021 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2020 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2020 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $299K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Cartesian Therapeutics (NASDAQ: RNAC) do?
- Cartesian Therapeutics is a clinical-stage biotechnology company developing mRNA-based cell therapies aimed at treating autoimmune diseases. It focuses on immunology and applies an mRNA platform to broaden the use of cell therapy for patients.
- Who founded Cartesian Therapeutics (NASDAQ: RNAC)?
- Cartesian Therapeutics (NASDAQ: RNAC) was founded by Metin Kurtoglu, Omid Farokhzad.
- Who are Cartesian Therapeutics (NASDAQ: RNAC)'s investors?
- Cartesian Therapeutics (NASDAQ: RNAC)'s investors include K2 HealthVentures, Maryland TEDCO, Schooner Capital, TEDCO, +ND Capital, Polaris Partners, RUSNANO.
- How much funding has Cartesian Therapeutics (NASDAQ: RNAC) raised?
- Cartesian Therapeutics (NASDAQ: RNAC) has disclosed $405.1M raised across 12 of its 15 known rounds.
- Where is Cartesian Therapeutics (NASDAQ: RNAC) headquartered?
- Cartesian Therapeutics (NASDAQ: RNAC) is headquartered in Watertown, US.